Skip to content

Glaukos GKOS Research and development expense

Research and development expense at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$3.53B+9.4%
Boston Scientific logo
Boston ScientificBSX
$516M+16.5%
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Revenue$150.6M+41.2%
Gross profit$117.2M+42.4%
Operating income-$19.9M+4.0%
Net income-$19.8M-9.0%
EPS (diluted)-$0.34-6.3%

Balance sheet

See full
Cash & equivalents$104.2M-8.8%
Total debt$105.9M-1.7%
Total equity$670.9M-12.2%
Total assets$893.3M-7.5%

Cash flow

See full
Operating cash flow-$12.5M+32.4%
CapEx$4.0M+104%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$7.68B+12.3%
Enterprise value$7.68B+12.5%
P/S13.9×-3.0×

Profitability

See full
Gross margin78.1%+2.3pp
Operating margin-36.1%+24.3pp
Net margin-34.3%+4.8pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26.4%+11.1pp
Debt / equity0.2×0.0×
Current ratio5.4×-1.1×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Glaukos’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Glaukos's research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Glaukos's research and development expense?
Glaukos (GKOS) reported research and development expense of $44.15M in Q1 2026.
How has Glaukos's research and development expense changed year-over-year?
Glaukos's research and development expense increased by 36.4% year-over-year, from $32.35M to $44.15M.
What is the long-term trend for Glaukos's research and development expense?
Over 4 years (2021 to 2025), Glaukos's research and development expense has grown at a 10.5% compound annual growth rate (CAGR), from $101M to $150.61M.